109 related articles for article (PubMed ID: 19656290)
1. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.
Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
J Viral Hepat; 2010 Jan; 17(1):34-50. PubMed ID: 19656290
[TBL] [Abstract][Full Text] [Related]
2. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
[TBL] [Abstract][Full Text] [Related]
3. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
Lidgren M; Hollander A; Weiland O; Jönsson B
Scand J Gastroenterol; 2007 Jul; 42(7):867-77. PubMed ID: 17558912
[TBL] [Abstract][Full Text] [Related]
4. Therapy of hepatitis C: cost-effectiveness analysis.
Koff RS
Hepatology; 1997 Sep; 26(3 Suppl 1):152S-155S. PubMed ID: 9305681
[TBL] [Abstract][Full Text] [Related]
5. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
Sheerin IG; Green FT; Sellman JD
Drug Alcohol Rev; 2004 Sep; 23(3):261-72. PubMed ID: 15370005
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness analysis of the treatment of chronic hepatitis C].
Joliot E; Vanlemmens C; Kerleau M; Le Gales C; Woronoff-Lemsi MC; Flori YA; Seror V; Hrusovsky S; Monnet E; Bresson-Hadni S; Miguet JP
Gastroenterol Clin Biol; 1996; 20(11):958-67. PubMed ID: 9119185
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
Aggarwal R; Ghoshal UC; Naik SR
Natl Med J India; 2002; 15(6):320-7. PubMed ID: 12540064
[TBL] [Abstract][Full Text] [Related]
8. Advances in the treatment of hepatitis C.
Lawrence SP
Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
[TBL] [Abstract][Full Text] [Related]
9. Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients.
Buti M; Wong J; Casado MA; Esteban R
J Hepatol; 2006; 44(1 Suppl):S60-4. PubMed ID: 16360235
[TBL] [Abstract][Full Text] [Related]
10. An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there!
Rubin A; Berenguer M
Liver Transpl; 2010 Jun; 16(6):697-700. PubMed ID: 20517902
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
[TBL] [Abstract][Full Text] [Related]
12. Trends in viral hepatitis cost-effectiveness studies.
Saab S; Choi Y; Rahal H; Li K; Tong M
Am J Manag Care; 2012 Dec; 18(12):790-8. PubMed ID: 23286609
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.
John-Baptiste A; Yeung MW; Leung V; van der Velde G; Krahn M
Pharmacoeconomics; 2012 Nov; 30(11):1015-34. PubMed ID: 23050771
[TBL] [Abstract][Full Text] [Related]
14. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C.
Gao X; Stephens JM; Carter JA; Haider S; Rustgi VK
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):335-43. PubMed ID: 22812557
[TBL] [Abstract][Full Text] [Related]
15. Review of cost-effectiveness studies of pegylated therapies for hepatitis C.
Shaya FT; Klaskala W; Mullins CD
Expert Rev Pharmacoecon Outcomes Res; 2005 Jun; 5(3):339-51. PubMed ID: 19807603
[TBL] [Abstract][Full Text] [Related]
16. [Financial burden of hepatitis C infection and its treatment].
Makara M; Hunyady B
Orv Hetil; 2015 May; 156(21):862-8. PubMed ID: 26038994
[TBL] [Abstract][Full Text] [Related]
17. [New drugs for hepatitis C].
Färkkilä M
Duodecim; 2014; 130(18):1813-22. PubMed ID: 25558623
[TBL] [Abstract][Full Text] [Related]
18. Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment.
Siebert U; Sroczynski G; ;
Ger Med Sci; 2003 Nov; 1():Doc07. PubMed ID: 19675705
[TBL] [Abstract][Full Text] [Related]
19. The science, economics, and effectiveness of combination therapy for hepatitis C.
Dusheiko G; Barnes E; Webster G; Whalley S
Gut; 2000 Aug; 47(2):159-61. PubMed ID: 10896900
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of treatment for chronic hepatitis C.
Koff RS
J Hepatol; 1999; 31 Suppl 1():255-8. PubMed ID: 10622598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
